Anoop Patel

Associate Professor

Duke University
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Purpose: Exhaustion represents a collection of programmed T-cell differentiation states and an important mode of T-cell dysfunction. T-cell progression from progenitor to terminal exhaustion is associated with upregulation of the transcription factor thymocyte selection–associated HMG box (TOX). Our understanding of factors regulating TOX expression and the transition from progenitor to terminal exhaustion, however, remains incomplete. Experimental Design: Single-cell RNA sequencing was used to evaluate the expression of TNF receptors on human and murine tumor-infiltrating CD8 + T cells. Flow cytometry was utilized to assess exhaustion markers and TNF receptors on CD8 + T cells. Bulk RNA sequencing was used to demonstrate the role of TNFR2 on the overall exhaustion profile. Finally, the effect of TNFR2 on the overall antitumor response was established using TNFR2-knockout (KO) mice and an antagonist. Results: We reveal that upregulation of TNFR2 coincides with the gain of phenotypic markers and functions reflective of terminal exhaustion. Loss of TNFR2 affords a novel population of T cells that expresses TIM3 but possesses diminished TOX levels and contains functional characteristics of both progenitor and terminally exhausted cells. TIM3 + TNFR2-KO T cells exhibit reduced exhaustion transcriptional programs and enhanced AP1 pathway signatures. Finally, TNFR2-KO mice demonstrate improved T cell–dependent control of tumor and chronic lymphocytic choriomeningitis infection, whereas pharmacologic antagonism of TNFR2 licenses responses to checkpoint blockade in multiple subcutaneous and intracranial tumor models. Conclusions: Our data place TNFR2 signaling as a potential upstream regulator of TOX expression in T cells and propose TNFR2 antagonism as a novel immunotherapeutic strategy.

Year:

2026

Median time to humane endpoint for subcutaneous (sc) implantation of E0771 and CT2A-Trp2 or intracranial (ic) implantation of CT2A-Trp2 or CT2A. Median survival was not reached in the aTNFR2/aPD1 combination group following intracranial CT2A-Trp2 as 12 out of 20 survived long-term (more than 60 days) and intracranial CT2A (6/10 survived).

Year:

2026

The human neocortex underlies higher cognition and is the engine of complex thought. Yet our understanding of its neuronal diversity is limited by sparse access to tissue, inconsistent sampling across studies, and a lack of multiple modality data. Although single-cell transcriptomic taxonomies are an important framework for characterizing cell type diversity, transcriptomic information alone cannot reveal the cellular properties that define neuronal computations. To address this, we performed Patch-seq, a method for collecting Morphology, Electrophysiology, and Transcriptomic data from a single neuron. We focused on glutamatergic, neocortical, excitatory neurons, the principal long-range projecting neurons of the cortex, and systematically integrated their morphoelectric features with transcriptomic identity. In combination with spatial transcriptomic data, we interrogated 39 of 42 transcriptomically-defined neuron types with a layer-centric perspective. Morphoelectric properties, such as cortical depth, apical dendrite structure, and excitability clearly distinguish transcriptomic subclasses and support many finer transcriptomic types. Morphoelectric properties are influenced by spatial location in supragranular layers, while deeper layers exhibit greater heterogeneity. Cross-species comparisons reveal conserved subclass organization but pronounced differences in apical dendrite arborization between mouse and human, and surprising similarities between human and macaque. Together, these datasets provide a unified multimodal reference that advances our understanding of human cortical circuitry and establishes a foundation for experimental and computational studies of human brain function and disease.

Year:

2026

The physiological properties of human and rodent neurons differ, yet the extent to which these differences reflect human specializations is often unclear. Compared with their rodent counterparts, human supragranular pyramidal neurons possess enriched HCN-channel-dependent intrinsic membrane properties and a related sensitivity to synaptic inputs containing delta/theta band frequencies. We tested whether other primate species possess enriched HCN-channel dependent membrane properties. We found ubiquitous HCN1 subunit gene expression in supragranular glutamatergic neurons across New World Monkeys, Old-World Monkeys, and great apes in single nucleus RNA-sequencing datasets. Using Patch-seq recordings from acute and cultured brain slices, we found robust HCN-dependent physiological properties in supragranular pyramidal neurons in a species of New-World monkey ( Saimiri sciureus ) and two species of Old-World Monkey ( Macaca mulatta, Macaca nemestrina ). In both human and macaque neocortex, HCN-related intrinsic properties increased in magnitude with increasing laminar depth, especially in one transcriptomic cell type. Within this type, HCN dependent properties were more pronounced in macaque than human neurons. These findings indicate that HCN-governed membrane properties and sensitivity to delta/theta band frequencies are roughly conserved in supragranular pyramidal neurons across at least 36 million years of primate evolution.

Year:

2025

Many cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma. Evolocumab is a clinically approved PCSK9 inhibitor, which restores MHC-I expression in pre-clinical cancer models. However, monoclonal antibodies (mAbs) have limited blood brain/tumor barrier penetrance (BBB/BTB). The aim of this window-of-opportunity trial was to evaluate evolocumab’s BBB/BTB penetrance and biological effect in glioma (PesKE; NCT04937413). Patients with newly diagnosed/recurrent glioma undergoing a clinically indicated biopsy or resection were enrolled (n=32, M: 16, F: 16; control average age: 51.85, evolocumab: 53). Intervention participants (n=6) received subcutaneous evolocumab 4-14 days pre-procedure. 4/6 intervention participants provided research tissue. No significant adverse events were observed. Evolocumab was detected in all analyzed intervention tissue, with an average tumor:blood ratio of 0.0222 (SD±0.0190), akin to other mAbs. Evolocumab quantitation was 4.44x greater in contrast-enhancing (mean 0.0068 fmol/mcg (SD±0.001)) vs non-contrast enhancing cases (mean 0.0015 fmol/mcg (SD±0.0004)). Proteomic analysis found positive trends between evolocumab and MHC-I subtypes (HLA-A-C, E-G), with a significant positive correlation with HLA-H (R2=0.9584, p=0.021*). Tumor tissue with higher evolocumab titers demonstrated increased surface MHC-I and CD8+ T cell infiltration. Increased CD8+ TNF, FASLG and GZMA transcription was observed in high titer tissue compared to low titer tissue/untreated controls. Pre-resection evolocumab is well tolerated but exhibits BBB/BTB penetrance akin to other mAbs. Increased tumoral evolocumab/PCSK9i may enhance tumoral MHC-I/effector CD8+ infiltration. Future work will explore combining evolocumab with BBB/BTB opening therapies like low-intensity focused ultrasound. One Sentence Summary: We conducted a tissue-based study in glioma patients to evaluate if peripheral evolocumab enters tumors, enhances surface MHC-I, and boosts effector CD8+ T cell infiltration.

Year:

2025

Single-cell transcriptomics has unveiled a vast landscape of cellular heterogeneity in which the cell cycle is a significant component. We trained a high-resolution cell cycle classifier (ccAFv2) using single cell RNA-seq (scRNA-seq) characterized human neural stem cells. The ccAFv2 classifies six cell cycle states (G1, Late G1, S, S/G2, G2/M, and M/Early G1) and a quiescent-like G0 state (Neural G0), and it incorporates a tunable parameter to filter out less certain classifications. The ccAFv2 classifier performed better than or equivalent to other state-of-the-art methods even while classifying more cell cycle states, including G0. We demonstrate that the ccAFv2 classifier effectively generalizes the S, S/G2, G2/M, and M/Early G1 states across cell types derived from all three germ layers. While the G0, G1, and Late G1 states perform well in neuroepithelial cell types, their accuracy is lower in other cell types. However, misclassifications are confined to the G0, G1, and Late G1 states. We showcased the versatility of ccAFv2 by successfully applying it to classify cells, nuclei, and spatial transcriptomics data in humans and mice, using various normalization methods and gene identifiers. We provide methods to regress the cell cycle expression patterns out of single cell or nuclei data to uncover underlying biological signals. The classifier can be used either as an R package integrated with Seurat or a PyPI package integrated with SCANPY. We proved that ccAFv2 has enhanced accuracy, flexibility, and adaptability across various experimental conditions, establishing ccAFv2 as a powerful tool for dissecting complex biological systems, unraveling cellular heterogeneity, and deciphering the molecular mechanisms by which proliferation and quiescence affect cellular processes.

Year:

2024

Grade IV glioma, formerly known as glioblastoma multiforme (GBM) is the most aggressive and lethal type of brain tumor, and its treatment remains challenging in part due to extensive interpatient heterogeneity in disease driving mechanisms and lack of prognostic and predictive biomarkers. Using mechanistic inference of node-edge relationship (MINER), we have analyzed multiomics profiles from 516 patients and constructed an atlas of causal and mechanistic drivers of interpatient heterogeneity in GBM (gbmMINER). The atlas has delineated how 30 driver mutations act in a combinatorial scheme to causally influence a network of regulators (306 transcription factors and 73 miRNAs) of 179 transcriptional “programs”, influencing disease progression in patients across 23 disease states. Through extensive testing on independent patient cohorts, we share evidence that a machine learning model trained on activity profiles of programs within gbmMINER significantly augments risk stratification, identifying patients who are super-responders to standard of care and those that would benefit from 2 nd line treatments. In addition to providing mechanistic hypotheses regarding disease prognosis, the activity of programs containing targets of 2 nd line treatments accurately predicted efficacy of 28 drugs in killing glioma stem-like cells from 43 patients. Our findings demonstrate that interpatient heterogeneity manifests from differential activities of transcriptional programs, providing actionable strategies for mechanistically characterizing GBM from a systems perspective and developing better prognostic and predictive biomarkers for personalized medicine.

Year:

2024

Collaborators (32)

Trygve Bakken

Allen Institute for Brain Science

UNITED STATES
View details

Rachel Dalley

Allen Institute for Brain Science

UNITED STATES
View details

Natalia Goriounova

University of Amsterdam

NETHERLANDS
View details

Christiaan de Kock

Assistent Professor

VU Amsterdam

NETHERLANDS
View details

Richard Ellenbogen

Professor and Chairman

University of Washington

UNITED STATES
View details

Mustafa Khasraw

Professor

Duke University

UNITED STATES
View details

Huib Mansvelder

University of Amsterdam

NETHERLANDS
View details

Peter E. Fecci

Chair and Professor

Duke University Medical Center

UNITED STATES
View details

Katayoun Ayasoufi

Assistant Professor

Duke University

UNITED STATES
View details

Eline Jasmijn Mertens

Assistant professor

Nyenrode Business University

NETHERLANDS
View details

Jason Scott Hauptman

Assistant Professor

University of Washington

UNITED STATES
View details

Hongkui Zeng

Executive Director

Allen Institute for Brain Science

UNITED STATES
View details

Christohper Plaisier

Assistant Professor

Arizona State University

UNITED STATES
View details

Sarah Walling-Bell

Allen Institute

UNITED STATES
View details

Andrew Ko

Assistant Professor

University of Washington

UNITED STATES
View details

Chuan-Yuan Li

Professor and Vice Chair for Research

Duke University School of Medicine

UNITED STATES
View details

Matthew Foster

Duke University

UNITED STATES
View details

Boudewijn Lelieveldt

Delft University of Technology

NETHERLANDS
View details

Jeffrey Ojemann

Professor

University of Washington

UNITED STATES
View details

Gábor Tamás

European Research Council Advanced Scholar and Professor of Neuroscience

University of Szeged

HUNGARY
View details

Brian Kalmbach

Allen Institute for Brain Science

UNITED STATES
View details

Brian Long

Allen Institute for Brain Science

UNITED STATES
View details

Jean-Philippe Hugnot

Professor

University of Montpellier

FRANCE
View details

Daniel Wilkinson

Assistant Research Professor

University of Colorado Cancer Center

UNITED STATES
View details

Benjamin Bartelle

Assistant Professor

Massachusetts Institute of Technology

UNITED STATES
View details

Charles Cobbs

Swedish Neuroscience Institute

UNITED STATES
View details

Annick Desjardins

Professor of Neurosurgery and Neurology

Duke University

UNITED STATES
View details

Simon G. Gregory

Professor

Duke University

UNITED STATES
View details

ROGER MCLENDON

Professor

Duke University School of Medicine

UNITED STATES
View details

Manuel Ferreira

-

UNITED STATES
View details

Herman Tung

Allen Institute

UNITED STATES
View details

Samuel Emerson

Assistant Professor

University of Washington

UNITED STATES
View details